Impact of Anti-hyperglycemic Medications on Bone Health

Research output: Contribution to journalReview article

2 Scopus citations

Abstract

Diabetes has recently emerged as an independent risk factor for osteoporosis and osteoporotic fractures, and the underlying mechanisms are starting to be unveiled. Medications used in the treatment of diabetes may impact skeletal health in part through glycemic control. In addition, specific classes of anti-hyperglycemic medications directly influence bone metabolism. In particular, thiazolidinedione use is clearly associated with greater fracture risk. Preliminary studies suggest that medications that enhance the incretin effect (GLP-1 receptor analogs and DPP-4 inhibitors) could have a bone-protective effect, whereas SGLT-2 inhibitors could increase fracture risk. This manuscript reviews the impact of anti-hyperglycemic medications on bone health.

Original languageEnglish (US)
Pages (from-to)43-52
Number of pages10
JournalClinical Reviews in Bone and Mineral Metabolism
Volume13
Issue number1
DOIs
StatePublished - Feb 27 2015

Keywords

  • Anti-hyperglycemic
  • Diabetes
  • Fracture
  • Medications
  • Osteoporosis

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Orthopedics and Sports Medicine
  • Endocrinology

Fingerprint Dive into the research topics of 'Impact of Anti-hyperglycemic Medications on Bone Health'. Together they form a unique fingerprint.

  • Cite this